This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

  • Products
  • Therapy Areas
  • Resources
  • Events & Webinars
  • Learning Zone
  • Podcasts
Performance you can trust hero banner image

EYLEA® (aflibercept) 8 mg

Overview

CONFIDENCE IN EYLEA® (aflibercept) 8 mg

PERFORMANCE YOU CAN TRUST

Give your eligible patients up to 6 months in nAMD and DMO, and up to 5 months in RVO between treatment visits through fast and sustained drying, with 4x the molar dose of a tried-and-tested molecule.

 

  • Mean CRT reductions in the EYLEA 8 mg 8q8/3 arm (QUASAR) were -342.5 µm 4 weeks after 1 dose and reduction was maintained through to Week 64.
  • Mean CRT reductions in the EYLEA 8 mg 8q16 arm were -128 µm (PULSAR) and -127 µm (PHOTON) 4 weeks after 1 dose and reduction was maintained through Weeks 96-156.

EYLEA 114.3 mg/mL is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (nAMD), visual impairment due to diabetic macular oedema (DMO) and visual impairment due to macular oedema secondary to retinal vein occlusion (branch, central and hemiretinal RVO).

 

Prescribing information for EYLEA® (aflibercept) can be found here.

VIEW THE DRYING, DURABILITY AND SAFETY DATA FOR EACH OF THE EYLEA 8 mg PIVOTAL TRIALS BELOW.

nAMD

Licenced for treatment intervals from Q4 to Q24*

Explore EYLEA 8 mg in nAMD (PULSAR)

DMO

Licenced for treatment intervals from Q4 to Q24*

Explore EYLEA 8 mg in DMO (PHOTON)

RVO

Licenced for treatment intervals from Q4 to Q20*

Explore EYLEA 8 mg in RVO (QUASAR)

4x the molar dose of a tried and tested molecule, with a safety profile consistent with EYLEA 2 mg.

*For patients who are initiating treatment, EYLEA is administered with 1 injection per month for 3 consecutive doses. In nAMD/DMO, injection intervals may then be extended up to every 4 months based on the physician’s judgement of visual and/or anatomic outcomes. Subsequently, the treatment intervals may be further extended up to Q24, such as with a treat-and-extend dosing regimen, while maintaining stable visual and/or anatomic outcomes. In RVO, injection intervals may then be extended based on the physician’s judgement of visual and/or anatomic outcomes. Consult the SmPC for full posology.

Please refer to the links below to hear from other experts who have used EYLEA 8 mg, and explore a variety of on-demand resources created in collaboration with both local and internationally recognised leaders in medical retina.

Abbreviations

DMO, diabetic macular oedema. nAMD, neovascular age-related macular degeneration. Q4, every 4 weeks. Q20, every 20 weeks. Q24, every 24 weeks. RVO, retinal vein occlusion. SmPC, Summary of Product Characteristics.

PP-EYL-GB-3129 | March 2026

    • 1
      EYLEA® 114.3 mg/mL Summary of Product Characteristics.
    • 2
      Korobelnik JF, et al. Ophthalmology 2026;133:39–50.
    • 3
      Do DV, et al. Ophthalmology 2025:S0161-6420(25)00707–9.
    • 4
      Chaudhary V, et al. Aflibercept 8 mg in macular edema following retinal vein occlusion: Week 64 results from the QUASAR trial. Angiogenesis, Exudation, and Degeneration. 7 February 2026. Virtual. Oral presentation.
    • 5
      Wong TY. Three-year outcomes of aflibercept 8 mg in nAMD: Safety and efficacy results from the PULSAR extension study. Angiogenesis, Exudation, and Degeneration. 8 February 2025. Virtual. Oral presentation.
    • 6
      Do DV. Aflibercept 8mg in DME: Key results from the PHOTON extension study. AAO 2024. 18–21 October 2024. Chicago, USA. Oral presentation.